In the pursuit of improved therapies for metastatic breast cancer, a succession of drugs have been approved that target a range of mechanisms. However, resistance to these therapies is inevitably encountered. This resistance underscores the emergence and perhaps persistence of compensatory pathways that allow cancer cells to survive. Hormone-directed strategies are integral in the management of hormone receptor-positive breast cancer, because they effectively target the oestrogen receptor signalling pathway. Ongoing research aims to explore the synergistic effects of additive therapies in this space. Notable examples include the CDK4/6 inhibitors, such as palbociclib, abemaciclib, and ribociclib, several of which have been reported to confer a survival advantage upon addition to the selective oestrogen receptor degrader fulvestrant.^, 

中文翻译：

---

Capivasertib抑制转移性乳腺癌的关键途径。

在寻求用于转移性乳腺癌的改良疗法时，已经批准了针对一系列机制的一系列药物。但是，不可避免地会遇到对这些疗法的抵抗。这种抵抗力强调了使癌细胞存活的代偿途径的出现，并可能持续存在。激素控制策略在激素受体阳性乳腺癌的治疗中不可或缺，因为它们有效地靶向雌激素受体信号传导途径。正在进行的研究旨在探索该领域中附加疗法的协同作用。值得注意的例子包括CDK4 / 6抑制剂，例如palbociclib，abeciclib和ribociclib，据报道其中几种抑制剂在添加选择性雌激素受体降解剂氟维司群后具有生存优势。^，